Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Novartis thin-strip OTCs?

This article was originally published in The Tan Sheet

Executive Summary

Novartis and Adhesive Research's ARx division are expanding their work on developing Thin Strip offerings and have broken ground on a new facility that will be used to manufacture products employing the technology, the firms announce May 19. ARx Division already supports six thin film products, including Triaminic Thin Strips and Theraflu Thin Strips, both introduced by Novartis (1"The Tan Sheet" April 26, 2004, p. 13). ARx is the exclusive developer and supplier of active films for Novartis, and plans to launch 20 new products over the next three years. The firm is also developing a 25,000 square-foot facility, to be located on the ARx campus in Glen Rock, Penn. Novartis' launch of its thin strip products is "just the beginning of a relationship that will benefit from this new state-of-the-art facility"...

You may also be interested in...



Novartis Expects Thin Strips Technology To Drive OTC Cough/Cold Sales

Novartis Consumer Health is gearing up to launch new cough/cold products using a Thin Strips dosage form this summer

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel